Gilead Follows Up Wall St. Hot Streak with Big Money Alliances
Executive Summary
An enviable cash position gives Gilead the luxury of making agreements like licensing exclusive ex-US rights to Vistide to Pharmacia & Upjohn. They also entered a broader deal with Hoffmann-La Roche surrounding its neuraminidase inhibitor program for influenza treatment.